This was associated with a significant decrease in the levels of Treg cells and immature myeloid cells. targeted by various chemotherapeutic agents to produce favorable antitumor immune responses. Therefore , utilizing cancer drugs to enhance host antitumor immunity should be considered a feasible therapeutic approach; and recent characterization of the immunomodulatory mechanisms of anticancer chemotherapy using both new and traditional cytotoxic agents suggests that combinations of these approaches with classical immunomodulatory agents could lead to a viable new therapeutic paradigm for the treatment of cancer. Keywords: Chemotherapy, Low dose chemotherapy, Chemoimmunomodulation, Tumor immunoenvironment, Immunosuppression, Immunotherapy, Cancer therapy, Immune regulators == Introduction == Cancer remains the second most common cause of death in the United States, accounting for nearly 1 of every 4 deaths in this country. More than 1 . 6 million new cancer cases are expected to be diagnosed in 2013; and almost 600, 000 Americans are projected to die of cancer, equivalent to about 1, 600 people per day [1]. Since the advent of the age of systemic cancer drug therapy, treatment strategies have been dominated by the use of cytotoxic chemotherapeutic agents for the majority of cancer types. From 1948, when Farber et al. introduced aminopterin, the first chemotherapeutic agent, more than 100 such agents have come into use in clinical practice [2]. While significant advances have been made since that time, such as the development of novel classes of drugs and the use of combinatorial therapies, most drug regimens continue to be based on the traditional, maximum tolerated dose (MTD) regimen. While such a strategy has found success in the treatment of various neoplasms, MTD drug therapy is associated with significant morbidity such as myelosuppression, neurotoxicity and damage to the gut mucosa and TGR5-Receptor-Agonist hair follicles. Treating cancer with cytotoxic drugs is also limited by the inherent genetic instability of cancerous cells, which results in the expansion of drug-resistant cancer mutants and the acquired resistance to chemotherapeutic agents. As such, future advances in the pharmacological treatment of cancer will require an alternative strategy for targeting this TGR5-Receptor-Agonist group of more than 200 diseases (Table1). == Table 1 . == Examples of primary targets of chemotherapeutic approaches Chemotherapeutic approaches were grouped based on the reported doses in relation to Maximum Tolerated Dose (MTD). Conventional chemotherapy, ~MTD; Metronomic chemotherapy, repeated ~1/3-1/5 MTD; Low-dose chemotherapy, single or short-term ~1/31/10 MTD; Chemomodulation, ~1/101/30 MTD. Symbols:, cell death;, functional down-regulation;, functional up-regulation;, increased immunogenicity;?, unproven effects == Metronomic Chemotherapy == Over the past decade, a new paradigm has emerged in the pharmacological treatment of neoplastic disease termed metronomic chemotherapy, which involves the frequent administration of chemotherapeutic drugs at concentrations 310 times below the established MTD without breaks in dosing schedule for prolonged periods of time. For example , by using a dosing schedule of cyclophosphamide in the murine lung cancer and leukemia models that provided more sustained apoptosis of endothelial cells within the vascular bed of a tumor, it was shown that a chemotherapeutic agent can more effectively control tumor growth in mice, regardless of whether the tumor cells are drug resistant [3]. In the neuroblastoma xenograft model, continuous treatment with low doses of vinblastine resulted in significant xenograft regression, Rabbit Polyclonal to MRIP diminished tumor vascularity and direct inhibition of angiogenesis [4]. Such metronomic drug regimens offer the possibility to provide significant relief of the burden of disease while avoiding the significant morbidity encountered with higher dosing. The potential of metronomic chemotherapy was revealed in animal models and the efficacy of this approach has been confirmed in the clinic [5]. Although phase III evidence of the efficacy of this type of therapy is still several years away, evidence from phase II trials suggests that metronomic chemotherapy as an interesting alternative for either primary systemic therapy or maintenance therapy is safe and can be clinically beneficial in a broad range of tumors [6]. As opposed to targeting rapidly-dividing tumor cells with MTD therapy, metronomic therapy regimens primarily exert their effects on the vascular endothelial cells of the tumor, which are more sensitive to low concentrations of chemotherapeutic drugs than normal host or tumor cells [7]. When combined with angiogenesis inhibitors such as Bevacizumab (Avastin, a recombinant humanized monoclonal antibody that neutralizes the biological activity of human VEGF), metronomic chemotherapy may have TGR5-Receptor-Agonist significant clinical utility even in drug-resistant cancers [8]. However , it is important to note that tumor endothelial cells (TEC) quite differ from normal endothelial cells TGR5-Receptor-Agonist in many parameters, including cell proliferation, migration, gene profile and responses to growth factors and several chemotherapeutic drugs [9]. TEC may be genetically abnormal and might acquire drug resistance. For instance, TEC have been shown to be resistance to paclitaxel through greater mRNA expression of multidrug resistance 1,.